Skip to content
CityAM
Main navigation
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Tech
      • Banking
      • FTSE 100 Live
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • AON
      • Bayes Business School
      • Canada BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      Strait of Hormuz closed over ceasefire violations, says Iran

      Aerial view of ships navigating the strategic Strait of Hormuz, highlighting its importance to global maritime trade routes

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
    • From our partners
      • The Morning Briefing: SBS x CityAM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Platitudes in women’s sport are empty, patronising and offensive

      Business professionals in a conference room discussing strategy with a presentation screen displaying key market trends.

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      Fogo de Chao nominated for Best Casual Dining Toast award

      Fogo de Chão restaurant exterior with vibrant signage and bustling entrance at popular city location

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Events
  • Latest Paper
Wednesday 02 December 2020 2:00 pm  |  Updated:  Wednesday 02 December 2020 2:06 pm

Pfizer vaccine: Matt Hancock green-lights 800,000 doses for rollout next week

By: Poppy Wood

Add as a preferred source on Google
UK Government Announces Pfizer/BioNTech Covid Vaccine Approved For Use From Next Week
The health secretary has vouched to take the vaccine live on air to prove its safety

The NHS will start vaccinating the most vulnerable next week, after 800,000 doses of the Pfizer vaccine passed batch testing this morning, the health secretary has said.

Announcing the UK’s approval of the Pfizer/Biontech vaccine in the Commons this morning, Matt Hancock said: “I can confirm that batch testing has been completed this morning for the first deployment of 800,000 doses of the vaccine. These doses cover the whole United Kingdom.”

The Pfizer vaccine is 95 per cent effective and has passed the requisite safety checks by the Medical and Healthcare products Regulatory Agency (MHRA). 

The government has secured orders for 40m doses of the drug, alongside 317m doses of six other vaccines.

The Pfizer jab will be enough to vaccinate 20m people through two doses each.

Hancock chaired a meeting with health ministers from the devolved administrations this morning “to ensure the rollout is coordinated nationwide”.

The NHS has joined with the Armed Forces to begin urgent preparations to roll out the Pfizer/Biontech vaccine by the weekend, with the drug set to hit London in the next few weeks. 

Military personnel have been called in to transform around 10 sites into vaccine hubs within a fortnight, including the Nightingale hospital at London’s Excel centre. 

Every major city in the UK is set to host its own mass vaccination centre, while a further 1,000 small sites will be established across England. 

However, the health secretary urged cautious optimism over the news, warning that the UK’s vaccination “will be difficult”.

“This will be one of the biggest civilian logistical efforts that we’ve faced as a nation,” he said. “There will be challenges and complications, but I know that the NHS is equal to the task, rolling out the vaccine free at the point of delivery [and] according to clinical need — not ability to pay.”

Read more

Former Tory MP set to call Sunak in libel spat with Hancock

Andrew Bridgen

The Prime Minister welcomed the news this morning as “fantastic” and that vaccines will “ultimately allow us to reclaim our lives”.

Hancock announced there will also be a wide-scale “public information campaign” to boost trust in the vaccine’s safety, following concerns that efforts to vaccinate the population will be scuppered by anti-vaxxers.

The health secretary vouched to take the vaccine live on air to prove it was safe for public use, as the government prepares to armour the UK against disinformation.

MHRA chief Dr June Raine this morning assured the British public that “no corners have been cut” in assessing the safety of the Pfizer vaccine despite its swift timeline. 

Vaccines usually take around a decade from start to finish before they hit the shelves, whereas Pfizer’s will start public rollout within 10 months of being first developed.

“Our expert scientists and clinicians have worked round the clock, carefully and methodically poring over tables, analyses and graphs on hundreds of thousands of pages of data,” Raine added. “The safety of the public will always come first”.

It comes after Pfizer’s announcement this morning ignited conspiracy theories across social media sites.

“Thalidomide” was trending on Twitter just hours after the MHRA announced it had approved the jab from the US drugs firm. 

Read more: MPs to grill social media platforms over anti-vax conspiracies

The government last week said it has mobilised the army to utilise an elite “information warfare” unit to counter online propaganda against vaccines.

Leaked documents revealed that its soldiers are already monitoring cyberspace for Covid-19 content and analysing how British citizens are being targeted online.

Read more

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • Coronavirus
  • Matt Hancock
  • Vaccine

Trending Articles

  • As it happened: Stocks sink after Fed and Bank of England opt for hawkish hold; Oil price tumbles

  • FTSE 100 Live: Pound dips and stocks slip as Andy Burnham victory triggers political uncertainty

  • City investors raise alarm on Burnham’s Chancellor pick

  • Inheritance tax enquiries surge to six-year high after HMRC clampdown

  • More Big Four blues as Deloitte plans to slash UK audit roles

More from CityAM

  • Former Tory MP set to call Sunak in libel spat with Hancock

    Lawsuit
    Andrew Bridgen
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

    Business Wire
  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

    Business Wire
  • Suralink Launches Cloud Testing Suite to Bring Agentic Execution to Audit Engagements

    Business Wire
  • Cowes Week announces Horner-linked North Sails as title sponsor

    Sport Business
    There is insufficient context from the article content to create a specific and descriptive alt text for the image.
  • The Turnover: CityAM’s sport business newsletter

    Sport Business
    For a long time the sports desk at CityAM has been longing to read a sport business newsletter. So we created The Turnover.

CityAM Canada — business, markets and opinion for Canadian readers.

Sections

  • Business
  • Markets
  • Tech
  • AI
  • Economics
  • Opinion
  • Cities

Company

  • About
  • Contact

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 CityAM Canada. All rights reserved.
Terms · Privacy · Cookies